Advances in Therapeutic Agents for Diabetic Nephropathy
DOI:
https://doi.org/10.62836/amr.v5i1.0001Keywords:
Diabetic nephropathy, clinical strategy, pharmacological agentAbstract
Diabetic nephropathy, the prevalent microvascular complication of diabetes, presents a significant challenge to global healthcare systems. The pathogenesis is primarily driven by chronic hyperglycemia-induced renal damage, manifested as increased glomerular filtration rate, inflammation, and oxidative stress. Current clinical management aims to delay disease progression, reduce complications, and improve patients’ quality of life, utilizing agents such as renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists. Emerging therapies, including stem cell and gene therapies, are under active investigation to provide more effective treatment avenues. Furthermore, comprehensive strategies incorporating lifestyle medicine and nutritional supplementation show promise in diabetic nephropathy management and warrant further exploration. This review summarizes current clinical strategies and pharmacological agents for diabetic nephropathy and explores potential novel therapeutic strategies, aiming to provide a scientific reference for future research and clinical practice.
References
Deng W, Zhao L, Chen C, et al. National Burden and Risk Factors of Diabetes Mellitus in China from 1990 to 2021: Results from the Global Burden of Disease Study 2021. Journal of Diabetes 2024; 16(10): e70012. https://doi.org/10.1111/1753-0407.70012.
Samsu N. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. BioMed Research International 2021; 2021: 1497449. https://doi.org/10.1155/2021/1497449.
Fenta ET, Eshetu HB, Kebede N, et al. Prevalence and Predictors of Chronic Kidney Disease among Type 2 Diabetic Patients Worldwide, Systematic Review and Meta-Analysis. Diabetology & Metabolic Syndrome 2023; 15(1): 245. https://doi.org/10.1186/s13098-023-01202-x.
Gajjala PR, Sanati M, Jankowski J. Cellular and Molecular Mechanisms of Chronic Kidney Disease with Diabetes Mellitus and Cardiovascular Diseases as Its Comorbidities. Frontiers in immunology 2015; 6: 340. https://doi.org/10.3389/fimmu.2015.00340.
Mogensen CE, Christensen CK, Vittinghus E. The Stages in Diabetic Renal Disease: With Emphasis on the Stage of Incipient Diabetic Nephropathy. Diabetes 1983; 32: 64–78. https://doi.org/10.2337/diab.32.2.s64.
Rao V, Rao LV, Tan SH, et al. Diabetic Nephropathy: An Update on Pathogenesis and Drug Development. Diabetes & Metabolic Syndrome 2019; 13(1): 754–762. https://doi.org/10.1016/j.dsx.2018.11.054.
Thipsawat S. Early Detection of Diabetic Nephropathy in Patient with Type 2 Diabetes Mellitus: A Review of the Literature. Diabetes and Vascular Disease Research 2021; 18(6). https://doi.org/10.1177/14791641211058856.
Satirapoj B. Tubulointerstitial Biomarkers for Diabetic Nephropathy. Journal of Diabetes Research 2018; 2018: 2852398. https://doi.org/10.1155/2018/2852398.
Liu H, Feng J, Tang L. Early Renal Structural Changes and Potential Biomarkers in Diabetic Nephropathy. Frontiers in Physiology 2022; 13: 1020443. https://doi.org/10.3389/fphys.2022.1020443.
Ye Z, Xian W, Ling GU, et al. Efficacy of Danggui Buxue Decoction on Diabetic Nephropathy-Induced Renal Fibrosis in Rats and Possible Mechanism. Journal of Traditional Chinese Medicine 2023; 43(3): 507–513. https://doi.org/10.19852/j.cnki.jtcm.20230214.004.
Zhang R, Wang Q, Li Y, et al. A New Perspective on Proteinuria and Drug Therapy for Diabetic Kidney Disease. Frontiers in Pharmacology 2024; 15: 1349022. https://doi.org/10.3389/fphar.2024.1349022.
Zain M, Awan FR. Renin Angiotensin Aldosterone System (RAAS): Its Biology and Drug Targets for Treating Diabetic Nephropathy. Pakistan Journal of Pharmaceutical Sciences 2014; 27(5): 1379–1391.
Kilpatrick ES, Kallner A, Atkin SL, et al. The Variability of Measured and Calculated Low-Density Lipoprotein (LDL) Cholesterol in Statin-Treated Diabetes Patients. Annals of Clinical Biochemistry 2024; 62(3): 184–190. https://doi.org/10.1177/00045632241305936.
Gao FM, Ali AS, Bellomo R, et al. A Systematic Review and Meta-Analysis on the Safety and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor Use in Hospitalized Patients. Diabetes Care 2024; 47(12): 2275–2290. https://doi.org/10.2337/dc24-0946.
Sheu JY, Chang LY, Chen JY, et al. The Outcomes of SGLT-2 Inhibitor Utilization in Diabetic Kidney Transplant Recipients. Nature Communications 2024; 15(1): 10043. https://doi.org/10.1038/s41467-024-54171-8.
Sidra FNU, Agarwal S, Lockhart Pastor P, et al. Glucagon-Like Peptide-1 Receptor Agonists Versus Dipeptidyl-Peptidase 4 Inhibitors in Advanced Chronic Kidney Disease and End Stage Kidney Disease: Real World Effectiveness and Persistence of Therapy. Journal of Diabetes and its Complications 2024; 39(1): 108925. https://doi.org/10.1016/j.jdiacomp.2024.108925.
Ning X, Munir KM, Davis SN. Drugs Stimulating Insulin Secretion in Early Clinical Development for the Treatment of Type 1 Diabetes: What’s New? Expert Opinion on Investigational Drugs 2024; 33(12): 1199–1208. https://doi.org/10.1080/13543784.2024.2439501.
Weng SW, Kuo HM, Chuang JH, et al. Study of Insulin Resistance in Cybrid Cells Harboring Diabetes-Susceptible and Diabetes-Protective Mitochondrial Haplogroups. Mitochondrion 2013; 13(6): 888–897. https://doi.org/10.1016/j.mito.2013.08.001.
Solomon DH, Paynter NP, Guan H, et al. External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Anti-Inflammatory Drug Users: Real-World Application. ACR Open Rheumatology 2020; 2(5): 269–275. https://doi.org/10.1002/acr2.11134.
Zahoor MM, Mazhar S, Azhar A, et al. Factor Xa Inhibitors Versus Warfarin in Patients with Non-Valvular Atrial Fibrillation and Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Annals of Medicine and Surgery 2024; 86(2): 986–993. https://doi.org/10.1097/MS9.0000000000001621.
Chen YF, Li SJ, Chen QT. Analysis of Coagulation Function Changes and Influencing Factors of Hypercoagulable State in Type 2 Diabetic Nephropathy. Journal of Medicine & Frontier 2024; 14(02): 122–124.
Karihaloo A. Anti-Fibrosis Therapy and Diabetic Nephropathy. Current Diabetes Reports 2012; 12(4): 414–422. https://doi.org/10.1007/s11892-012-0290-7.
Avila G, Osornio-Garduño DS, Ríos-Pérez EB, et al. Functional and Structural Impact of Pirfenidone on the Alterations of Cardiac Disease and Diabetes Mellitus. Cell Calcium 2014; 56(5): 428–435. https://doi.org/10.1016/j.ceca.2014.07.008.
Zavatta G, Casadio E, Rinaldi E, et al. Aldosterone and Type 2 Diabetes Mellitus. Hormone Molecular Biology and Clinical Investigation 2016; 6(1): 53–59. https://doi.org/10.1515/hmbci-2015-0065.
Veneti S, Tziomalos K. The Role of Finerenone in the Management of Diabetic Nephropathy. Diabetes Therapy 2021; 12(7): 1791–1797. https://doi.org/10.1007/s13300-021-01085-z.
Li XC, Li XJ. Research Progress of Acupuncture and Moxibustion in Treating Diabetic Nephropathy. Inner Mongolia Journal of Traditional Chinese Medicine 2023; 42(11): 153–155. https://doi.org/10.16040/j.cnki.cn15-1101.2023.11.004.
Wang SH, Fang ZH, Li YF, et al. Research Progress on Internal Treatment of Diabetic Nephropathy with Traditional Chinese Medicine. Journal of Henan University (Medical Science) 2024; 43(05): 313–317+340. https://doi.org/10.15991/j.cnki.41-1361/r.2024.05.011.
Sun S, Zheng YL, Cheng H, et al. Research Progress on Traditional Chinese Medicine in Treating Diabetic Nephropathy. Integrated Traditional Chinese and Western Medicine Chronic Disease Journal 2025; 2(02): 89–96.
Hatipoglu BA, Blanchette J. Islet Cell Therapy and Stem Cell Therapy for Type 1 Diabetes: There Will Always Be a Hope. Endocrinology and Metabolism Clinics of North America 2023; 52(1): 187–193. https://doi.org/10.1016/j.ecl.2022.07.001.
Kioulaphides S, García AJ. Encapsulation and Immune Protection for Type 1 Diabetes Cell Therapy. Advanced Drug Delivery Reviews 2024; 207: 115205. https://doi.org/10.1016/j.addr.2024.115205.
Zhu JJ, Wilding JPH, Gu XS. Combining GLP-1 Receptor Agonists and SGLT-2 Inhibitors for Cardiovascular Disease Prevention in Type 2 Diabetes: A Systematic Review with Multiple Network Meta-Regressions. World Journal of Diabetes 2024; 15(10): 2135–2146. https://doi.org/10.4239/wjd.v15.i10.2135.
Nieto-Martinez R, Neira C, de Oliveira D, et al. Lifestyle Medicine in Diabetes Care: The Lifedoc Health Model. American Journal of Lifestyle Medicine 2022; 17(3): 336–354. https://doi.org/10.1177/15598276221103470.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Sha Meng, Ximei Cai Cai, Fang Wang
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommerical-NoDerivatives 4.0 International License.
